Business Description
Sandoz Group AG
SIC : 2834
ISIN : US7999261008
Share Class Description:
SDZNY: ADRTotal Employee Number:
23,000Compare
Compare
Traded in other countries / regions
SDZ.Switzerland0SAN.UKSDZNY.USASDZ.AustriaD8Y.GermanySDZN.Mexico IPO Date
2023-10-04Description
Sandoz Group AG is a Swiss generics and biosimilars pharmaceutical company, spun off from Novartis and listed independently in October 2023. It develops, manufactures, and markets off-patent medicines, with a portfolio spanning generic small molecules, complex injectables, value-added medicines, and biosimilars. Generics account for the large majority of sales, while biosimilars represent a growing share; Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, and the first US biosimilar, Zarxio, in 2015, and markets numerous biosimilar products with a substantial pipeline. Its customers include wholesalers, pharmacies, hospitals, and healthcare providers, and it operates across Europe, the United States, and other international markets. Revenue comes from product sales of generic and biosimilar pharmaceuticals, supported by manufacturing scale and a broad global commercial footprint.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.2 | |||||
Equity-to-Asset | 0.4 | |||||
Debt-to-Equity | 0.69 | |||||
Debt-to-EBITDA | 3.77 | |||||
Interest Coverage | 4.92 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 2.51 | |||||
Beneish M-Score | -2.79 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 0.4 | |||||
3-Year EBITDA Growth Rate | -0.4 | |||||
3-Year EPS without NRI Growth Rate | 15.9 | |||||
3-Year FCF Growth Rate | -4.9 | |||||
3-Year Book Growth Rate | -3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 13.91 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 8.06 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 58.93 | |||||
9-Day RSI | 48.94 | |||||
14-Day RSI | 47.3 | |||||
3-1 Month Momentum % | 6.96 | |||||
6-1 Month Momentum % | 15.21 | |||||
12-1 Month Momentum % | 51.22 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.05 | |||||
Quick Ratio | 0.72 | |||||
Cash Ratio | 0.15 | |||||
Days Inventory | 174.98 | |||||
Days Sales Outstanding | 77.43 | |||||
Days Payable | 110.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.2 | |||||
Dividend Payout Ratio | 0.35 | |||||
Forward Dividend Yield % | 1.2 | |||||
5-Year Yield-on-Cost % | 1.2 | |||||
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | 0.28 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 47.8 | |||||
Operating Margin % | 9.15 | |||||
Net Margin % | 5.53 | |||||
EBITDA Margin % | 14.1 | |||||
FCF Margin % | 11.9 | |||||
OCF Margin % | 16.67 | |||||
ROE % | 7.07 | |||||
ROA % | 2.9 | |||||
ROIC % | 4.41 | |||||
3-Year ROIIC % | 1.33 | |||||
ROC (Joel Greenblatt) % | 33.92 | |||||
ROCE % | 7.05 | |||||
Years of Profitability over Past 10-Year | 3 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 57.57 | |||||
Forward PE Ratio | 18.41 | |||||
PE Ratio without NRI | 57.57 | |||||
PS Ratio | 3.29 | |||||
PB Ratio | 4.16 | |||||
Price-to-Free-Cash-Flow | 39.81 | |||||
Price-to-Operating-Cash-Flow | 19.56 | |||||
EV-to-EBIT | 39.53 | |||||
EV-to-Forward-EBIT | 15.17 | |||||
EV-to-EBITDA | 25.38 | |||||
EV-to-Forward-EBITDA | 12.76 | |||||
EV-to-Revenue | 3.6 | |||||
EV-to-Forward-Revenue | 3.27 | |||||
EV-to-FCF | 30.23 | |||||
Price-to-GF-Value | 1.64 | |||||
Earnings Yield (Greenblatt) % | 2.53 | |||||
FCF Yield % | 3.77 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:SDZNY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sandoz Group AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 11,620.311 | ||
| EPS (TTM) ($) | 1.475 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 26.56 | ||
| 14-Day RSI | 47.3 | ||
| 14-Day ATR ($) | 1.983976 | ||
| 20-Day SMA ($) | 84.946 | ||
| 12-1 Month Momentum % | 51.22 | ||
| 52-Week Range ($) | 55.417 - 94.15 | ||
| Shares Outstanding (Mil) | 432.69 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sandoz Group AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sandoz Group AG Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-25 09:30 | In 157 days | ||
| Annual report for 2026 | 2027-02-25 | In 156 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-25 | In 156 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-30 09:00 | In 39 days | ||
| Third quarter earnings results for 2026 | 2026-10-30 | In 38 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 79.32 (-1.47%) | ||
| USD 1.020737 Cash Dividend | 2026-04-14 | 85.17 (+2.11%) | ||
| General meeting for 2026 | 2026-04-09 | 83.10 (-0.10%) | ||
| Jefferies Pan-European Mid-Cap Conference | 2026-03-25 | 75.94 (+0.77%) | ||
| BNP Paribas Exane Healthcare Conference | 2026-03-24 | 76.57 (+1.61%) |
Show
Entries
Sandoz Group AG Frequently Asked Questions
What is Sandoz Group AG(SDZNY)'s stock price today?
The current price of SDZNY is $84.91. The 52 week high of SDZNY is $94.15 and 52 week low is $55.42.
When is next earnings date of Sandoz Group AG(SDZNY)?
The next earnings date of Sandoz Group AG(SDZNY) is 2026-10-30 Est..
Does Sandoz Group AG(SDZNY) pay dividends? If so, how much?
The Dividend Yield %  of Sandoz Group AG(SDZNY) is 1.2% (As of Today), Highest Dividend Payout Ratio of Sandoz Group AG(SDZNY) was 0.35. The lowest was 0.18. And the median was 0.19. The  Forward Dividend Yield % of Sandoz Group AG(SDZNY) is 1.2%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform | 2026-08-17 |
Headlines
See More- 1
Sep 08, 2026
Switzerland's Sandoz aims to double sales by 2035 in expanded biosimilars push
Seeking Alpha • 4:38am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers